Biotricity Inc. (Biotricity) has announced the expansion of its cardiac diagnostics portfolio through strategic partnerships with a leading home-based neurology company and a leading home-based sleep apnea diagnostic company. Individuals suffering from sleep or neurological disorders have elevated risks for cardiac issues. These collaborations position Biotricity and its partners as comprehensive providers of holistic screenings, marking a significant advancement in Biotricity’s mission to offer integrated healthcare solutions that address the complex needs of patients with multiple conditions.

Biotricity Inc. (Biotricity) announces high demand for its latest breakthrough device, Biotres Pro. This device is easy to wear, resulting in excellent patient compliance and a higher selling price. Biotres Pro is expected to raise the average subscription price by over 32%.

Biotricity Inc. (Biotricity) announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics. Biotricity will work closely with healthcare professionals to optimize patient interaction protocols and streamline data collection processes. This cardiac monitoring pilot program is poised to showcase the revolutionary impact of Biotricity’s technology suite.

Biotricity Inc. (Biotricity) continues its strategic expansion with the announcement of its latest partnership in neurology to conduct cardiac screenings in patients suffering from neurological issues.  There are over 1,000 neurological disorders and over 100 million Americans suffering from at least 1 neurological issue. Alzheimer’s, Parkinsons, and other dementias are just a few such conditions that lead to increased cardiovascular risk. Many of these patients are screened late, leading to an increase in costs and higher patient risk. Biotricity is focused on providing earlier screenings to patients with co-morbidities, reducing costs while improving the quality of care.